Bellaye, P.-S. http://orcid.org/0000-0002-8498-5163
Moreau, M.
Raguin, O.
Oudot, A.
Bernhard, C.
Vrigneaud, J.-M.
Dumont, L.
Vandroux, D.
Denat, F.
Cochet, A.
Brunotte, F.
Collin, B.
Funding for this research was provided by:
Agence Nationale de la Recherche (“Investissements d’Avenir” (ANR-10-EQPX-05-01/ IMAPPI Equipex))
CNRS (3MIM integrated project (“Marquage de Molécules par les Métaux pour l’Imagerie Médicale”))
Université de Bourgogne (3MIM integrated project (“Marquage de Molécules par les Métaux pour l’Imagerie Médicale”))
Conseil Régional de Bourgogne (the “plan d'actions régional pour l'innovation (PARI)”)
European Union (PO FEDER-FSE Bourgogne 2014/2020 programs)
Article History
Received: 15 January 2018
Accepted: 26 April 2018
First Online: 17 May 2018
Compliance with ethical standards
:
: All authors have declared that no competing interest exists.
: All applicable international, national, and/or institutional guidelines for the care and use of animals were followed. All animal studies were sanctioned by the accredited Ethical committees (Oncomet n°91 and C2ea Grand Campus n°105) and were carried out in accordance to the legislation on the use of laboratory animals (directive 2010/63/EU). All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Experiments were conducted following the European Union’s animal care directive (86/609/EEC).
: Informed consent was obtained from all individual participants included in the study. Patient consent for the establishment of PDX (Patient-Derived Xenograft) models were developed by the CREMEC consortium and provided by OncodesignSuperscript removed (Dijon, France).
: Not applicable.